Dengue vaccine development and dengue viral neutralization and enhancement assays

Antiviral Therapy

Volumn 14, Issue 6, 2009, Pages 739-749

  Jin, Xia ^a   Block, Olivia Tono ^a   Rose, Robert ^a   Schlesinger, Jacob ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX; DENGUE VACCINE; DNA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; BRAIN PROTECTION; CLINICAL TRIAL; DENGUE; DNA IMMUNIZATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VACCINATION; VACCINE PRODUCTION; VIRUS ENCEPHALITIS; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS VIRULENCE;

ANIMALS; DENGUE VACCINES; DENGUE VIRUS; HUMANS; NEUTRALIZATION TESTS;

EID: 72049132084     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1288     Document Type: Review

References (88)

1. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007; 5:518-528.
2. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 2008; 4:229-238.
3. Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viraemia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990-1000. (Pubitemid 38373090)
4. Sun W, Nisalak A, Gettayacamin M, et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 2006; 193:1658-1665. (Pubitemid 43839470)
5. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-481.
6. Roehrig JT. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. Geneva: World Health Organization 2007.
7. Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78:4761-4775. (Pubitemid 38501097)
8. Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927-6934.
9. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001; 77:195-262.
10. Simmons CP, Chau TN, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 2007; 196:416-424. (Pubitemid 47093892)
11. Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140:527-533.
12. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989; 11 Suppl 4:S830-S839.
13. Innis BL, Eckels KH. Progress in development of a liveattenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 2003; 69:1-4.
14. Halstead SB. The Alexander D Langmuir Lecture. The pathogenesis of dengue. Molecular epidemiology in infectious disease. Am J Epidemiol 1981; 114:632-648.
15. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 1945; 101:640-642.
16. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30-50.
17. Dorrance WR, Frankel JW, Gordon I, Patterson PR, Schlesinger RW, Winter JW. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 1956; 77:352-364.
18. Dulbecco R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci U S A 1952; 38:747-752.
19. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-290.
20. Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18 Suppl 2:44-47. (Pubitemid 30252002)
21. Eckels KH, Dubois DR, Putnak R, et al. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg 2003; 69:12-16.
22. Kanesa-Thasan N, Edelman R, Tacket CO, et al. Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: selection of safe and immunogenic monovalent vaccines. Am J Trop Med Hyg 2003; 69:17-23.
23. Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
24. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent liveattenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009; 5:33-40.
25. Kanesa-thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-3188. (Pubitemid 32324047)
26. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 2002; 66:264-272. (Pubitemid 34756095)
27. Sanchez V, Gimenez S, Tomlinson B, et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 2006; 24:4914-4926. (Pubitemid 43782690)
28. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006; 2:60-67.
29. Blaney JE, Jr., Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol J 2007; 4:23.
30. Blaney JE, Jr., Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 2004; 4:39.
31. Whitehead SS, Falgout B, Hanley KA, Blaney JE, Jr., Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77:1653-1657.
32. Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered on-stru pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:3930-3937.
33. Durbin AP, McArthur JH, Marron JA, et al. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin 2006; 2:255-260.
34. Durbin AP, McArthur J, Marron JA, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin 2006; 2:167-173. (Pubitemid 44422483)
35. Durbin AP, Whitehead SS, McArthur J, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-718.
36. Raviprakash K, Porter KR, Kochel TJ, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81:1659-1667.
37. Putnak RJ, Coller BA, Voss G, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and liveattenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442-4452.
38. Russell PK, Udomsakdi S, Halstead SB. Antibody response in dengue and dengue hemorrhagic fever. Jpn J Med Sci Biol 1967; 20:103-108.
39. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004; 113:946-951.
40. Jin X. Cellular and molecular basis of antibody-dependent enhancement in human dengue pathogenesis. Future Virol 2008; 3:343-361.
41. Rodrigo WW, Alcena DC, Kou Z, et al. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vaccine Immunol 2009; 16:285-287.
42. Rodrigo WWSI, Alcena DC, Rose RC, Jin X, Schlesinger JJ. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg 2009; 80:61-65.
43. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-451.
44. Edelman R. Dengue and dengue vaccines. J Infect Dis 2005; 191:650-653.
45. Russell PK, Nisalak A. Dengue virus identification by the plaque reduction neutralization test. J Immunol 1967; 99:291-296.
46. Blaney JE, Jr., Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79:5516-5528.
47. Peiris JS, Porterfield JS. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 1979; 282:509-511.
48. Kontny U, Kurane I, Ennis FA. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol 1988; 62:3928-3933.
49. Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman MG. Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull 2005; 29:49-57.
50. Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 1990; 144:3183-3186.
51. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and proinflammatory cytokine production, in THP-1 cells. J Gen Virol 2007; 88:365-375.
52. Diamond MS, Edgil D, Roberts TG, Lu B, Harris E. Infection of human cells by dengue virus is modulated by different cell types and viral strains. J Virol 2000; 74:7814-7823. (Pubitemid 30641625)
53. Kou Z, Quinn M, Chen H, et al. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol 2008; 80:134-146. (Pubitemid 350220099)
54. Rodrigo WWSI, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by on-structcompetent and on-struct-incompetent human FcγRIA (CD64) or FcγRIIA (CD32). J Virol 2006; 80:10128-10138. (Pubitemid 44522606)
55. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109. (Pubitemid 38222779)
56. Guy B, Chanthavanich P, Gimenez S, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004; 22:3563-3574. (Pubitemid 39099632)
57. Blackley S, Kou Z, Chen H, et al. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol 2007; 81:13325-13334.
58. Boonnak K, Slike BM, Burgess TH, et al. Role of dendritic cells in antibody dependent enhancement of dengue infection. J Virol 2008; 82:3939-3951.
59. Diamond MS, Harris E. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. Virology 2001; 289:297-311. (Pubitemid 33141009)
60. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 2000; 74:4957-4966. (Pubitemid 30313834)
61. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 2004; 78:2701-2710. (Pubitemid 38314329)
62. Shresta S, Sharar KL, Prigozhin DM, Snider HM, Beatty PR, Harris E. Critical roles for both STAT1- dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J Immunol 2005; 175:3946-3954. (Pubitemid 41292056)
63. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-737. (Pubitemid 39023305)
64. Mosca JD, Pitha PM. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol Cell Biol 1986; 6:2279-2283.
65. Halstead SB. Measuring dengue enhancing antibodies: caveats. J Infect Dis 2006; 193:601.
66. Burke DS, Kliks S. Antibody-dependent enhancement in dengue virus infections. J Infect Dis 2006; 193:601-603. (Pubitemid 43202754)
67. Green S, Libraty DH, Laoprasopwattana K, Ennis FA, Rothman AL. Reply to Halstead and to Burke and Kliks. J Infect Dis 2006; 193:603-604.
68. Vorndam V, Beltran M. Enzyme-linked immunosorbent assay-format microneutralization test for dengue viruses. Am J Trop Med Hyg 2002; 66:208-212. (Pubitemid 34755655)
69. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197:823-829. (Pubitemid 36437860)
70. Lambeth CR, White LJ, Johnston RE, de Silva AM. Flow cytometry-based assay for titrating dengue virus. J Clin Microbiol 2005; 43:3267-3272.
71. Martin NC, Pardo J, Simmons M, et al. An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. J Virol Methods 2006; 134:74-85.
72. Putnak JR, de la Barrera R, Burgess T, et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 2008; 79:115-122. (Pubitemid 351957214)
73. Rodrigo WWSI, Alcena DC, Kou Z, et al. Divergent neutralization of American and Asian genotype dengue-2 is magnified in human Fcg receptor-expressing CV-1 cells. Clin Vaccine Immunol 2009; 16:285-287.
74. Kochel TJ, Raviprakash K, Hayes CG, et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000; 18:3166-3173. (Pubitemid 30345698)
75. Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006; 80:9577-9585. (Pubitemid 44435632)
76. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5:953-964.
77. Clark MR, Stuart SG, Kimberly RP, Ory PA, Goldstein IM. A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol 1991; 21:1911-1916.
78. van Royen-Kerkhof A, Sanders EA, Wijngaarden S, et al. Flow cytometric determination of FcgammaRIIa (CD32) polymorphism. J Immunol Methods 2004; 294:135-144. (Pubitemid 39626598)
79. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
80. Anderson CL, Ryan DH, Looney RJ, Leary PC. Structural polymorphism of the human monocyte 40 kilodalton Fc receptor for IgG. J Immunol 1987; 138:2254-2256. (Pubitemid 17046280)
81. Warmerdam PA, van de Winkel JG, Gosselin EJ, Capel PJ. Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med 1990; 172:19-25.
82. Huang KJ, Yang YC, Lin YS, et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 2006; 176:2825-2832.
83. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47.
84. Wang F, Gao X, Barrett JW, et al. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PloS Pathog 2008; 4:e1000099.
85. Hornung V, Ellegast J, Kim S, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314:994-997.
86. Diaz MO, Ziemin S, Le Beau MM, et al. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 1988; 85:5259-5263. (Pubitemid 18192946)
87. Hahon N, Booth JA. Benzo[a]pyrene: kinetics of in vitro bioactivation in relation to inhibition of viral interferon induction. J Interferon Res 1988; 8:151-167. (Pubitemid 18104924)
88. Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. A single amino acid substitution in the West Nile virus on-structural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 2006; 80:2396-2404. (Pubitemid 43271545)